These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 33737571)

  • 1. 4-methylumbelliferone-mediated polarization of M1 macrophages correlate with decreased hepatocellular carcinoma aggressiveness in mice.
    Rodríguez MM; Onorato A; Cantero MJ; Domínguez L; Bayo J; Fiore E; García M; Atorrasagasti C; Canbay A; Malvicini M; Mazzolini GD
    Sci Rep; 2021 Mar; 11(1):6310. PubMed ID: 33737571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12.
    Rodríguez MM; Fiore E; Bayo J; Atorrasagasti C; García M; Onorato A; Domínguez L; Malvicini M; Mazzolini G
    Mol Ther; 2018 Dec; 26(12):2738-2750. PubMed ID: 30301668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-methylumbelliferone inhibits hepatocellular carcinoma growth by decreasing IL-6 production and angiogenesis.
    Piccioni F; Fiore E; Bayo J; Atorrasagasti C; Peixoto E; Rizzo M; Malvicini M; Tirado-González I; García MG; Alaniz L; Mazzolini G
    Glycobiology; 2015 Aug; 25(8):825-35. PubMed ID: 25882295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.
    Zhong M; Zhong C; Cui W; Wang G; Zheng G; Li L; Zhang J; Ren R; Gao H; Wang T; Li X; Che J; Gohda E
    BMC Cancer; 2019 May; 19(1):439. PubMed ID: 31088527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma.
    Malvicini M; Fiore E; Ghiaccio V; Piccioni F; Rizzo M; Olmedo Bonadeo L; García M; Rodríguez M; Bayo J; Peixoto E; Atorrasagasti C; Alaniz L; Aquino J; Matar P; Mazzolini G
    Mol Ther; 2015 Sep; 23(9):1444-55. PubMed ID: 26105158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
    Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
    Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice.
    Piccioni F; Malvicini M; Garcia MG; Rodriguez A; Atorrasagasti C; Kippes N; Piedra Buena IT; Rizzo MM; Bayo J; Aquino J; Viola M; Passi A; Alaniz L; Mazzolini G
    Glycobiology; 2012 Mar; 22(3):400-10. PubMed ID: 22038477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting hyaluronan metabolism-related molecules associated with resistant tumor-initiating cells potentiates chemotherapy efficacy in lung cancer.
    Díaz MA; Fusco M; Benítez CA; Gayet F; García L; Victoria L; Jaramillo S; Bayo J; Zubieta MR; Rizzo MM; Piccioni F; Malvicini M
    Sci Rep; 2024 Jul; 14(1):16803. PubMed ID: 39039104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization.
    Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z
    Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycosylated 4-methylumbelliferone as a targeted therapy for hepatocellular carcinoma.
    Weiz G; Molejon MI; Malvicini M; Sukowati CHC; Tiribelli C; Mazzolini G; Breccia JD
    Liver Int; 2022 Feb; 42(2):444-457. PubMed ID: 34800352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy.
    Deng L; He K; Pan Y; Wang H; Luo Y; Xia Q
    Int J Med Sci; 2021; 18(10):2109-2116. PubMed ID: 33859517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular vesicles-derived OncomiRs mediate communication between cancer cells and cancer-associated hepatic stellate cells in hepatocellular carcinoma microenvironment.
    Li J; Yan Y; Ang L; Li X; Liu C; Sun B; Lin X; Peng Z; Zhang X; Zhang Q; Wu H; Zhao M; Su C
    Carcinogenesis; 2020 Apr; 41(2):223-234. PubMed ID: 31140556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo.
    Garcia MG; Bayo J; Bolontrade MF; Sganga L; Malvicini M; Alaniz L; Aquino JB; Fiore E; Rizzo MM; Rodriguez A; Lorenti A; Andriani O; Podhajcer O; Mazzolini G
    Mol Pharm; 2011 Oct; 8(5):1538-48. PubMed ID: 21770423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
    Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
    J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
    Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
    Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.